Kimitsu Chuo Hospital

Kisarazu-shi 292-8535

1 studies enrolling now · 6 studies all time

What they study most

Acute Coronary Syndrome, Acute Myocardial Infarction, Bladder Cancer, Receptors, Fibroblast Growth Factor, Urinary Bladder Neoplasms, Urothelial Cancer

Studies at this site

• A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Running, not enrolling
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction — Enrolling by invitation
• A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) — Running, not enrolling
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations — Completed